BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27553586)

  • 1. Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.
    Karlowee V; Amatya VJ; Hirano H; Takayasu T; Nosaka R; Kolakshyapati M; Yoshihiro M; Takeshima Y; Sugiyama K; Arita K; Kurisu K; Yamasaki F
    Pathobiology; 2017; 84(2):99-107. PubMed ID: 27553586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy Number Profiling of Brazilian Astrocytomas.
    Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
    G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
    Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
    Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
    J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
    Odia Y; Varma H; Tsankova NM
    Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
    Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
    Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
    PIAO YS; LU DH; ZHANG XJ; TANG GC; YANG H
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):156-60. PubMed ID: 21575384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
    Dong L; Pu PY; Wang H; Wang GX; Kang CS; Jiao DR
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
    Ishizawa K; Hirose T; Sugiyama K; Kageji T; Nobusawa S; Homma T; Komori T; Sasaki A
    Clin Neuropathol; 2012; 31(2):67-76. PubMed ID: 22385787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
    Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
    Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical and molecular study of long-term survival glioblastomas].
    Wang X; Liu YH; Xie F; You C; Mao Q
    Zhonghua Wai Ke Za Zhi; 2013 Feb; 51(2):166-70. PubMed ID: 23711013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.